Developer docs
API playgroundTry for free, no card

Search company profiles

Hesperos

Full company profile

uuid00024sz

Namestring
Hesperos
Legal namestring
Hesperos, Inc.
Websiteurl
hesperosinc.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Hesperos, Inc. is a privately held contract research organization (CRO) founded in 2015 in Orlando, Florida, by Drs. Michael L. Shuler and James J. Hickman. The company was the first spin-off from the NIH/DARPA Tissue Chip Program and the first to reach Phase IIb of that program's funding. It provides preclinical drug discovery and toxicity testing services through its patented Human-on-a-Chip platform, a pumpless, serum-free, gravity-driven microfluidic system that connects multiple human organ modules (heart, liver, neurons, skeletal muscle, kidney, GI tract, skin, blood-brain barrier, immune system, and pancreas) in a single recirculating circuit. Configurations range from two-organ standard models (Heart-Liver, Neuromuscular Junction) up to a ten-organ custom system, supporting both acute and chronic dosing studies for up to 28 days. Functional real-time readouts (contractile force, beat frequency, field potential duration, neuronal action potentials) and integrated PK-PD modeling via computational fluid dynamics (CFD) and HPLC-MS distinguish the platform from biomarker-only approaches.

Hesperos generates revenue through custom contract research engagements sold directly to pharmaceutical, biotechnology, cosmetic, food, and government clients. Services include custom multi-organ model builds, standardized safety/efficacy assays, disease modeling (rare diseases, cancer, neurodegeneration, ALS, Alzheimer's), drug-drug interaction studies, and PK-PD analyses. Pricing is quote-based with multi-year contracts; no public pricing exists. The company markets primarily through peer-reviewed scientific publications, scientific conferences and AIMBE workshops, its website (with 'Get a Quote' and webinar scheduling), and direct B2B sales engagement. Named enterprise customers and partners include Sanofi (SAR445088, the first FDA-approved drug using exclusively organoid-derived preclinical data), Roche, AstraZeneca, Vanda Pharmaceuticals, and Bayer Consumer Health. Government funding sources include NCATS, NIH, and DARPA. The company operates from a single Orlando headquarters at 12501 Research Pkwy, Suite 100, with 11-50 employees, and holds granted patents covering multi-organ systems, the pumpless platform, and serum-free culture methods.

Short descriptiontext

Hesperos is a private Orlando-based CRO operating a patented, pumpless, serum-free multi-organ Human-on-a-Chip microphysiological platform. It provides custom preclinical safety, efficacy, and PK-PD testing services to pharmaceutical, biotechnology, consumer-health, and government clients, with 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip systems, preclinical drug testing, microphysiological platforms, contract research services, multi-organ disease models
Industry3 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services (Organ-on-Chip)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Hesperos operates as a contract research organization providing compound safety and efficacy testing services using its Human-on-a-Chip platform. Services include custom build and standard systems composed of human cells for preclinical drug discovery and development.

hesperosinc.com
2Custom Model Development
TypeProfessional Services
Description

Custom development of multi-organ models with up to 5-organ or tissue types for specific therapeutic applications and disease modeling requirements.

hesperosinc.com
3Standard Model Testing Services
TypeProfessional Services
Description

Pre-configured testing services including 2-organ (Heart-Liver), 3-organ (Heart-Liver-Cancer), 4-organ (Heart-Liver-Neuron-Muscle), and neuromuscular junction models for safety and efficacy evaluation.

hesperosinc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom Contract Research Services
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available - requires consultation and custom quote through website contact/quote form

hesperosinc.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Hesperos is a contract research organization that provides preclinical drug discovery and toxicity testing services using its proprietary Human-on-a-Chip multi-organ microphysiological platform. The company delivers custom and standard in vitro models that interconnect human organ modules (heart, liver, neurons, muscle, kidney, GI, skin, BBB, immune system) under pumpless, serum-free, gravity-driven flow to simultaneously assess efficacy, off-target toxicity, ADME, drug-drug interactions, and PK/PD relationships for pharmaceutical, biotechnology, cosmetic, and government clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • First FDA-authorized Phase II clinical trial using efficacy data exclusively from a microphysiological system
+3 more records
Product overview1 text field

Hesperos offers the Human-on-a-Chip® platform as its core product - a multi-organ microphysiological system for drug discovery and toxicity testing. The platform supports configurable organ combinations from 2 to 5+ organs including Heart, Liver, Neurons, Skeletal Muscle, Kidney, GI Tract, Skin, and Blood-Brain Barrier. Standard pre-configured models include Heart-Liver (2-organ), Heart-Liver-Cancer (3-organ), Heart-Liver-Neuron-Muscle (4-organ), Neuromuscular Junction, and Heart-Liver-Skin. Custom organ configurations are available. Additional services include PK/PD modeling using computational fluid dynamics (CFD) and HPLC-MS quantification. The pumpless, serum-free platform can operate for up to 28 days for acute and chronic dosing studies.

Product and service9 records
1Human-on-a-Chip Platform
CategoryContract Research Platform
Description

A pumpless, serum-free, gravity-driven multi-organ microphysiological system platform that interconnects interchangeable organ modules to reproduce functional aspects of human physiology for drug discovery and toxicity testing. Used as the technological basis for all Hesperos CRO engagements with pharmaceutical, biotechnology, cosmetic, and government clients.

2Heart-Liver 2-Organ Model
CategoryStandard Multi-Organ Testing Service
Description

A two-organ standard testing service combining cardiac and hepatic tissue modules, supporting acute and chronic dosing studies for up to 28 days for safety and efficacy evaluation of drug candidates.

3Heart-Liver-Cancer 3-Organ Model
CategoryStandard Multi-Organ Testing Service
Description

A three-organ standard testing service integrating cardiac, hepatic, and cancer cell modules to evaluate chemotherapeutic efficacy and determine therapeutic index by simultaneously measuring efficacy and off-target toxicity.

4Heart-Liver-Neuron-Muscle 4-Organ Model
CategoryStandard Multi-Organ Testing Service
Description

A four-organ standard testing service with extensive baseline physiological characterization using multi-electrode array and cantilever-based functional readouts, particularly suited for neurodegenerative and CNS-active drug studies.

5Neuromuscular Junction (NMJ) Model
CategoryStandard Multi-Organ Testing Service
Description

A two-organ standard testing service for studying neuromuscular junction formation, stability, and activity between motoneuron neurotransmitter release and skeletal muscle contraction, with applications in ALS and other NMJ disease drug development.

6Heart-Liver-Skin 3-Organ Model
CategoryStandard Multi-Organ Testing Service
Description

A three-organ standard testing service for evaluating the safety and efficacy of topically applied products, with monitoring of transdermal diffusion and downstream effects on systemic organ physiology.

7Custom Multi-Organ Model Development
CategoryCustom CRO Testing Service
Description

Bespoke development of multi-organ microphysiological configurations tailored to client therapeutic application or disease modeling requirements, supporting up to 10 interconnected organ modules.

8Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling
CategoryAnalytical / Modeling Service
Description

Standalone computational service using computational fluid dynamics (CFD) modeling to derive pharmacokinetic profiles and PK/PD relationships from Hesperos multi-organ system experimental data, supporting drug development decision-making.

9HPLC-MS Analysis
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Strategic channel sales partnership announced for better predictive, more efficient, and lower cost drug/product development services.

2Bayer Consumer Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaborative peer-reviewed study to model central nervous system stress responses and evaluate potential therapeutics using human-relevant microphysiological system. Study demonstrated cortisol disrupts neuronal network activity.

mobihealthnews.com
3Vanda Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Collaboration on potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S published in Molecular Therapy Nucleic Acids. Also studying tradipitant CNS drug.

hesperosinc.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration on SAR445088 development - the first drug approved by FDA using exclusively organoid-derived preclinical data from Hesperos' human-on-a-chip system. Efficacy data from Hesperos system enabled FDA authorization of Phase II clinical trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collaboration on multi-organ cancer therapeutic evaluation and innate immune system modeling published in Advanced Science. Demonstrated differential monocyte actuation in three-organ functional system.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Collaboration on pharmacokinetic-pharmacodynamic modeling study published in Nature Scientific Reports 2019. Explored temporal PK-PD relationships using organ-chip models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Hesperos was the first spin-off company from the NIH/DARPA Tissue Chip Program. First company to reach Phase IIb funding, awarded for proven technologies requiring additional effort for regulatory acceptance.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Research collaboration with UCF researchers including Human-on-a-Chip study on Alzheimer's disease peripheral neuromuscular pathology and ALS neuromuscular junction modeling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Founders Shuler and Hickman were funded in the initial grant period of NIH Tissue Chip Initiative, which partnered with FDA and DARPA to advance organ-on-chip technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct organ-on-chip competitor offering the Liver-Chip and other single/multi-organ microfluidic platforms. Pursues an instrument-plus-consumables model that contrasts with Hesperos' CRO model, and is the most frequently cited peer in disease-on-chip market reports.

TypeDirect peer
Description

Direct peer offering OrganoPlate microfluidic 3D tissue culture platforms for organ-on-chip applications. Comparable to Hesperos in target customer base (pharma/biotech preclinical) and disease-modeling use cases, though focused on plate-based throughput rather than interconnected multi-organ systems.

3CN Bio Innovations
TypeDirect peer
Description

Direct peer providing the PhysioMimix multi-organ microphysiological system for drug discovery and toxicology. Competes head-to-head with Hesperos in multi-organ MPS services for pharma preclinical pipelines.

TypeDirect peer
Description

Direct competitor offering multi-organ-chip (MOC) platforms combining several organ equivalents on a microfluidic chip. Closely comparable to Hesperos' multi-organ Human-on-a-Chip and frequently co-cited in MPS regulatory and academic literature.

TypeEmerging player
Description

3D microtissue and organoid provider for drug discovery and toxicology. Overlaps with Hesperos in disease modeling and preclinical safety/efficacy testing but specializes in spheroid/organoid formats rather than interconnected multi-organ chips.

TypeEmerging player
Description

3D bioprinting and tissue company with early work in liver and other tissue models. Shares the disease-modeling adjacency with Hesperos but takes a bioprinting-first approach to in vitro human tissue construction.

TypeBroad incumbent
Description

Large CRO offering preclinical safety, efficacy, and DMPK services. Comparable to Hesperos as a customer-facing preclinical CRO but does not specialize in MPS; instead operates broad safety/biology portfolios that compete for the same pharma preclinical budget.

8Labcorp (Early Development / Covance)
TypeBroad incumbent
Description

Global CRO providing preclinical and clinical drug development services. Comparable in serving the same pharma buyers with non-clinical testing services but at much larger scale and broader scope, without an MPS specialization.

TypeOthers
Description

Leading supplier of iPSC-derived cells used in organ-on-chip and disease-modeling workflows. Not a direct competitor but a key enabling supplier whose iPSC lines underpin Hesperos' organ modules (e.g., BBB, GI tract).

TypeOthers
Description

Federal funder and steward of the Tissue Chip Program from which Hesperos spun off. Functions as a research partner and grant provider rather than a competitor, but shapes the regulatory and funding landscape in which Hesperos operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hesperos

Preclinical Contract Research Services (Organ-on-Chip)hesperosinc.com

Hesperos is a private Orlando-based CRO operating a patented, pumpless, serum-free multi-organ Human-on-a-Chip microphysiological platform. It provides custom preclinical safety, efficacy, and PK-PD testing services to pharmaceutical, biotechnology, consumer-health, and government clients, with 11-50 employees.

What Hesperos does

Hesperos, Inc. is a privately held contract research organization (CRO) founded in 2015 in Orlando, Florida, by Drs. Michael L. Shuler and James J. Hickman. The company was the first spin-off from the NIH/DARPA Tissue Chip Program and the first to reach Phase IIb of that program's funding. It provides preclinical drug discovery and toxicity testing services through its patented Human-on-a-Chip platform, a pumpless, serum-free, gravity-driven microfluidic system that connects multiple human organ modules (heart, liver, neurons, skeletal muscle, kidney, GI tract, skin, blood-brain barrier, immune system, and pancreas) in a single recirculating circuit. Configurations range from two-organ standard models (Heart-Liver, Neuromuscular Junction) up to a ten-organ custom system, supporting both acute and chronic dosing studies for up to 28 days. Functional real-time readouts (contractile force, beat frequency, field potential duration, neuronal action potentials) and integrated PK-PD modeling via computational fluid dynamics (CFD) and HPLC-MS distinguish the platform from biomarker-only approaches.

Hesperos generates revenue through custom contract research engagements sold directly to pharmaceutical, biotechnology, cosmetic, food, and government clients. Services include custom multi-organ model builds, standardized safety/efficacy assays, disease modeling (rare diseases, cancer, neurodegeneration, ALS, Alzheimer's), drug-drug interaction studies, and PK-PD analyses. Pricing is quote-based with multi-year contracts; no public pricing exists. The company markets primarily through peer-reviewed scientific publications, scientific conferences and AIMBE workshops, its website (with 'Get a Quote' and webinar scheduling), and direct B2B sales engagement. Named enterprise customers and partners include Sanofi (SAR445088, the first FDA-approved drug using exclusively organoid-derived preclinical data), Roche, AstraZeneca, Vanda Pharmaceuticals, and Bayer Consumer Health. Government funding sources include NCATS, NIH, and DARPA. The company operates from a single Orlando headquarters at 12501 Research Pkwy, Suite 100, with 11-50 employees, and holds granted patents covering multi-organ systems, the pumpless platform, and serum-free culture methods.

Hesperos firmographics

Firmographics
Name
Hesperos
Legal name
Hesperos, Inc.
Website
https://hesperosinc.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Hesperos is a private Orlando-based CRO operating a patented, pumpless, serum-free multi-organ Human-on-a-Chip microphysiological platform. It provides custom preclinical safety, efficacy, and PK-PD testing services to pharmaceutical, biotechnology, consumer-health, and government clients, with 11-50 employees.
Ownership category
akta.pro rank

Hesperos industry classification

Industry
Product category
Preclinical Contract Research Services (Organ-on-Chip)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Organ-on-chip systems
  • Preclinical drug testing
  • Microphysiological platforms
  • Contract research services
  • Multi-organ disease models

Where Hesperos is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Hesperos business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Hesperos operates as a contract research organization providing compound safety and efficacy testing services using its Human-on-a-Chip platform. Services include custom build and standard systems composed of human cells for preclinical drug discovery and development.
  2. Custom Model Development: Custom development of multi-organ models with up to 5-organ or tissue types for specific therapeutic applications and disease modeling requirements.
  3. Standard Model Testing Services: Pre-configured testing services including 2-organ (Heart-Liver), 3-organ (Heart-Liver-Cancer), 4-organ (Heart-Liver-Neuron-Muscle), and neuromuscular junction models for safety and efficacy evaluation.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Contract Research Services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Hesperos product offering

Product offering

Core offering

Hesperos is a contract research organization that provides preclinical drug discovery and toxicity testing services using its proprietary Human-on-a-Chip multi-organ microphysiological platform. The company delivers custom and standard in vitro models that interconnect human organ modules (heart, liver, neurons, muscle, kidney, GI, skin, BBB, immune system) under pumpless, serum-free, gravity-driven flow to simultaneously assess efficacy, off-target toxicity, ADME, drug-drug interactions, and PK/PD relationships for pharmaceutical, biotechnology, cosmetic, and government clients.

Product overview

Hesperos offers the Human-on-a-Chip® platform as its core product - a multi-organ microphysiological system for drug discovery and toxicity testing. The platform supports configurable organ combinations from 2 to 5+ organs including Heart, Liver, Neurons, Skeletal Muscle, Kidney, GI Tract, Skin, and Blood-Brain Barrier. Standard pre-configured models include Heart-Liver (2-organ), Heart-Liver-Cancer (3-organ), Heart-Liver-Neuron-Muscle (4-organ), Neuromuscular Junction, and Heart-Liver-Skin. Custom organ configurations are available. Additional services include PK/PD modeling using computational fluid dynamics (CFD) and HPLC-MS quantification. The pumpless, serum-free platform can operate for up to 28 days for acute and chronic dosing studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Human-on-a-Chip Platform A pumpless, serum-free, gravity-driven multi-organ microphysiological system platform that interconnects interchangeable organ modules to reproduce functional aspects of human physiology for drug discovery and toxicity testing. Used as the technological basis for all Hesperos CRO engagements with pharmaceutical, biotechnology, cosmetic, and government clients.
  • Heart-Liver 2-Organ Model A two-organ standard testing service combining cardiac and hepatic tissue modules, supporting acute and chronic dosing studies for up to 28 days for safety and efficacy evaluation of drug candidates.
  • Heart-Liver-Cancer 3-Organ Model A three-organ standard testing service integrating cardiac, hepatic, and cancer cell modules to evaluate chemotherapeutic efficacy and determine therapeutic index by simultaneously measuring efficacy and off-target toxicity.
  • Heart-Liver-Neuron-Muscle 4-Organ Model A four-organ standard testing service with extensive baseline physiological characterization using multi-electrode array and cantilever-based functional readouts, particularly suited for neurodegenerative and CNS-active drug studies.
  • Neuromuscular Junction (NMJ) Model A two-organ standard testing service for studying neuromuscular junction formation, stability, and activity between motoneuron neurotransmitter release and skeletal muscle contraction, with applications in ALS and other NMJ disease drug development.
  • Heart-Liver-Skin 3-Organ Model A three-organ standard testing service for evaluating the safety and efficacy of topically applied products, with monitoring of transdermal diffusion and downstream effects on systemic organ physiology.
  • Custom Multi-Organ Model Development Bespoke development of multi-organ microphysiological configurations tailored to client therapeutic application or disease modeling requirements, supporting up to 10 interconnected organ modules.
  • Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Standalone computational service using computational fluid dynamics (CFD) modeling to derive pharmacokinetic profiles and PK/PD relationships from Hesperos multi-organ system experimental data, supporting drug development decision-making.
  • HPLC-MS Analysis

Quantifiable outcome

  • First FDA-authorized Phase II clinical trial using efficacy data exclusively from a microphysiological system
  • +3 more outcomes

Companies that use Hesperos

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Hesperos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Hesperos partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor and core.

  • AsedaSciencesminorChannel Partner/ Reseller/ Distributor · 1 January 2026Strategic channel sales partnership announced for better predictive, more efficient, and lower cost drug/product development services.
  • Bayer Consumer HealthcoreStrategic or Co-development Partner · 1 October 2025Collaborative peer-reviewed study to model central nervous system stress responses and evaluate potential therapeutics using human-relevant microphysiological system. Study demonstrated cortisol disrupts neuronal network activity.
  • Vanda PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2025Collaboration on potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S published in Molecular Therapy Nucleic Acids. Also studying tradipitant CNS drug.
  • SanoficoreStrategic or Co-development Partner · 1 January 2022Collaboration on SAR445088 development - the first drug approved by FDA using exclusively organoid-derived preclinical data from Hesperos' human-on-a-chip system. Efficacy data from Hesperos system enabled FDA authorization of Phase II clinical trial.
  • RochecoreStrategic or Co-development Partner · 1 January 2020Collaboration on multi-organ cancer therapeutic evaluation and innate immune system modeling published in Advanced Science. Demonstrated differential monocyte actuation in three-organ functional system.
  • AstraZenecacoreStrategic or Co-development Partner · 1 January 2019Collaboration on pharmacokinetic-pharmacodynamic modeling study published in Nature Scientific Reports 2019. Explored temporal PK-PD relationships using organ-chip models.
  • NIH/DARPA Tissue Chip ProgramcoreStrategic or Co-development Partner · 1 January 2015Hesperos was the first spin-off company from the NIH/DARPA Tissue Chip Program. First company to reach Phase IIb funding, awarded for proven technologies requiring additional effort for regulatory acceptance.
  • University of Central Florida (UCF)minorStrategic or Co-development Partner · 1 January 2015Research collaboration with UCF researchers including Human-on-a-Chip study on Alzheimer's disease peripheral neuromuscular pathology and ALS neuromuscular junction modeling.
  • NIH (NCATS)coreStrategic or Co-development Partner · 1 January 2012Founders Shuler and Hickman were funded in the initial grant period of NIH Tissue Chip Initiative, which partnered with FDA and DARPA to advance organ-on-chip technology.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Hesperos competitors and assessment

Company assessment

Direct peers

  • Emulate: Direct organ-on-chip competitor offering the Liver-Chip and other single/multi-organ microfluidic platforms. Pursues an instrument-plus-consumables model that contrasts with Hesperos' CRO model, and is the most frequently cited peer in disease-on-chip market reports.
  • Mimetas: Direct peer offering OrganoPlate microfluidic 3D tissue culture platforms for organ-on-chip applications. Comparable to Hesperos in target customer base (pharma/biotech preclinical) and disease-modeling use cases, though focused on plate-based throughput rather than interconnected multi-organ systems.
  • CN Bio Innovations: Direct peer providing the PhysioMimix multi-organ microphysiological system for drug discovery and toxicology. Competes head-to-head with Hesperos in multi-organ MPS services for pharma preclinical pipelines.
  • TissUse: Direct competitor offering multi-organ-chip (MOC) platforms combining several organ equivalents on a microfluidic chip. Closely comparable to Hesperos' multi-organ Human-on-a-Chip and frequently co-cited in MPS regulatory and academic literature.

Emerging players

  • InSphero: 3D microtissue and organoid provider for drug discovery and toxicology. Overlaps with Hesperos in disease modeling and preclinical safety/efficacy testing but specializes in spheroid/organoid formats rather than interconnected multi-organ chips.
  • Organovo: 3D bioprinting and tissue company with early work in liver and other tissue models. Shares the disease-modeling adjacency with Hesperos but takes a bioprinting-first approach to in vitro human tissue construction.

Broad incumbents

  • Charles River Laboratories: Large CRO offering preclinical safety, efficacy, and DMPK services. Comparable to Hesperos as a customer-facing preclinical CRO but does not specialize in MPS; instead operates broad safety/biology portfolios that compete for the same pharma preclinical budget.
  • Labcorp (Early Development / Covance): Global CRO providing preclinical and clinical drug development services. Comparable in serving the same pharma buyers with non-clinical testing services but at much larger scale and broader scope, without an MPS specialization.

Others

  • FUJIFILM Cellular Dynamics: Leading supplier of iPSC-derived cells used in organ-on-chip and disease-modeling workflows. Not a direct competitor but a key enabling supplier whose iPSC lines underpin Hesperos' organ modules (e.g., BBB, GI tract).
  • NCATS (NIH National Center for Advancing Translational Sciences): Federal funder and steward of the Tissue Chip Program from which Hesperos spun off. Functions as a research partner and grant provider rather than a competitor, but shapes the regulatory and funding landscape in which Hesperos operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Hesperos social profiles

Digital presence

Hesperos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hesperos leadership team

Management profile

Number of profiles

Profiles7 records

Hesperos funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hesperos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hesperos

What does Hesperos do?

Hesperos is a contract research organization that provides preclinical drug discovery and toxicity testing services using its proprietary Human-on-a-Chip multi-organ microphysiological platform. The company delivers custom and standard in vitro models that interconnect human organ modules (heart, liver, neurons, muscle, kidney, GI, skin, BBB, immune system) under pumpless, serum-free, gravity-driven flow to simultaneously assess efficacy, off-target toxicity, ADME, drug-drug interactions, and PK/PD relationships for pharmaceutical, biotechnology, cosmetic, and government clients.

Is Hesperos a public or private company?

Hesperos is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Hesperos founded?

Hesperos was founded in 2015. It employs 11 to 50 people.

Where is Hesperos based?

Hesperos is headquartered in Orlando, United States, in the North America region.

How does Hesperos make money?

Three revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are custom Model Development and standard Model Testing Services.

Who are Hesperos's main competitors?

Direct peers on record are Emulate, Mimetas, CN Bio Innovations and TissUse. Emerging players are InSphero and Organovo. Broad incumbents are Charles River Laboratories and Labcorp (Early Development / Covance). Others are FUJIFILM Cellular Dynamics and NCATS (NIH National Center for Advancing Translational Sciences).

Does Hesperos have an API?

No public API is recorded for Hesperos.

What industry is Hesperos in?

Hesperos's product category is Preclinical Contract Research Services (Organ-on-Chip). Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioengineeringAdvancing Drug Development: Chinese Medical Journal Reviews Organoid ModelsThis Chinese Medical Journal review article traces the evolution of organoid technology in drug development from the first intestinal organoid in 2009 to recent clinical applications, highlighting its role in reducing drug development costs and timelines while improving predictive accuracy over traditional models. The article documents key regulatory milestones including the 2022 FDA approval of SAR445088 (developed by Sanofi with Hesperos) as the first drug using exclusively organoid-derived preclinical data, and subsequent approvals for drugs from Beijing Xunsheng Biomedical, Merus, Hengrui Medicine, Beijing ArtMia Cure Pharmaceutical, and Qilu Pharmaceutical entering clinical pipelines. Regulatory frameworks from the FDA, EMA, and China's NMPA have embraced organoid platforms, supporting a shift toward personalized medicine and reduced reliance on animal testing.News-MedicalThe power of organoids in speeding up lifesaving drug developmentA scientific review published in the Chinese Medical Journal traces the evolution of organoid technology from the first intestinal organoid in 2009 to its current applications in drug screening, validation, and personalized medicine, highlighting how organoid models have overcome limitations of traditional preclinical testing. Regulatory frameworks in the US, EU, and China have increasingly endorsed organoid-based approaches, including the FDA Modernization Act 2.0 eliminating mandatory animal testing requirements. Several drugs including Sanofi-Hesperos' SAR445088 and Merus' MCLA-158 have entered clinical trials based entirely or significantly on organoid-derived preclinical data, demonstrating the technology's growing impact on accelerating drug development.SciTechDailyAlzheimer’s Symptoms May Start Outside the Brain, Study FindsResearchers at the University of Central Florida, collaborating with healthcare technology company Hesperos, found that movement-related symptoms of Alzheimer’s disease may originate in the peripheral nervous system rather than the brain. Using lab-grown human cell systems to mimic body functions, the team demonstrated that genetic mutations tied to familial Alzheimer’s can disrupt the neuromuscular junction independently of central nervous system input. These findings, published in Alzheimer’s & Dementia, suggest that motor deficits could serve as earlier indicators for detection and intervention.PatsnapOrgan-on-chip drug testing technology landscape 2026An analysis of 30 organ-on-chip patent records published between 2021 and 2024 reveals four distinct innovation waves, progressing from foundational single-organ proof-of-concept devices in 2021 to AI-augmented ten-organ human-on-a-chip platforms by 2024, with filing volumes accelerating from 4 records to 11 over the period. Regulatory agencies including the US FDA have begun accepting OoC data as supporting evidence in drug filings, converting the technology from a research curiosity into a commercially and regulatorily relevant tool for ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling. Key 2024 developments include Hesperos Inc.'s ten-organ human-on-a-chip system, Sanofi SA's AI digital twin framework for predicting in vivo drug responses, and Mimetas BV's GLP-compliant cartridge system designed explicitly for regulatory submission.University of Central FloridaUCF Study Suggests Some Alzheimer’s Symptoms May Begin Outside the BrainResearchers from the University of Central Florida and healthcare tech company Hesperos published a study in Alzheimer’s & Dementia suggesting that movement-related symptoms of familial Alzheimer's may originate in the peripheral nervous system rather than solely in the brain. The team utilized Hesperos' 'human-on-a-chip' technology to demonstrate that genetic mutations associated with the disease disrupt neuromuscular junctions independently of central nervous system involvement. This finding implies that early motor deficits could serve as diagnostic indicators and suggests that treatments targeting only the brain may be insufficient for addressing all aspects of the disease.Business Wire BlogHesperos Provides Support for an Investigational Product for a Phase II Clinical Trial with its Human-on-a-Chip®Hesperos announced that its Human-on-a-Chip® technology supported Dianthus Therapeutics' Investigational New Drug submission to the FDA for a Phase II clinical trial of DNTH103. The preclinical data demonstrated that the monoclonal antibody improves nerve cell transmission and reduces muscle fatigue in a neuromuscular junction model, validating its potential for treating generalized myasthenia gravis.MobiHealthNewsHesperos, Bayer Consumer Health team up to study central nervous system stressContract research organization Hesperos published a peer-reviewed study in conjunction with Bayer Consumer Health, introducing a human-relevant microphysiological system for modeling central nervous system stress responses and evaluating therapeutic compounds. The study found that chronic exposure to cortisol disrupts neuronal network activity and impairs long-term potentiation, mimicking stress-related cognitive decline, while Echinacea extract was shown to substantially alleviate these deficits. The research also demonstrates the potential of microphysiological platforms to replace traditional animal models in preclinical research on stress and neurodegenerative diseases.Market Research FutureUS Organ on chip Market Size, Industry Growth 2035The US organ-on-chip market was valued at $98.56 million in 2024 and is projected to grow to $144.68 million by 2035, reflecting a compound annual growth rate (CAGR) of 3.55% during the forecast period 2025-2035. Key drivers of market expansion include technological advancements in microfluidics and biomaterials, increasing demand for personalized medicine, growing regulatory support for alternatives to animal testing, and the integration of artificial intelligence for enhanced data analysis and predictive modeling. Major players in the market include Emulate, Organovo, Hesperos, InSphero, Hurel Corporation, and Naefin Technologies, which have recently undertaken strategic initiatives such as partnerships, product launches, and grant funding to advance organ-on-chip technologies for drug discovery and toxicology research applications.LinkedInArtificial Intelligence Brain Chips Market Size, Trends, Growth & Strategic Forecasts 2026-2033Verified Market Reports released a market analysis forecasting the Artificial Intelligence Brain Chips sector to grow from USD 3.50 billion in 2024 to USD 15.50 billion by 2033, driven by advancements in neuroprosthetics and AI algorithms. The report identifies key players such as Emulate, Hesperos, and Draper Laboratory while highlighting regulatory hurdles and ethical considerations as significant barriers to widespread clinical adoption.